FDA Inspection 1304468 — Kamlesh Kumar Sankhala, M.D.
The FDA completed an inspection of Kamlesh Kumar Sankhala, M.D. on February 17, 2026 in Beverly Hills, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 17, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beverly Hills, CA (United States)
Additional Details
Clinical Investigator (CI)